Protective effect of resveratrol against doxorubicin-induced cardiac toxicity and fibrosis in male experimental rats

Journal of Physiology and Biochemistry

Volumn 70, Issue 3, 2014, Pages 701-711

  Arafa, Manar Hamed ^a   Mohammad, Nanies Sameeh ^a   Atteia, Hebatallah Husseini ^b   Abd Elaziz, Hesham Radwan ^c  

^a ZAGAZIG UNIVERSITY   (Egypt)

^b Zagazig University   (Egypt)

^c ZAGAZIG UNIVERSITY   (Egypt)

Author keywords

Antioxidants; Cardiac fibrosis; Cardiotoxicity; Doxorubicin; Resveratrol

Indexed keywords

ANTIOXIDANT; CARDIOTONIC AGENT; CASP3 PROTEIN, RAT; CASPASE 3; DOXORUBICIN; GLUTATHIONE; MESSENGER RNA; RESVERATROL; STILBENE DERIVATIVE; SUPEROXIDE DISMUTASE; TGFB1 PROTEIN, RAT; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIOTOXICITY; DRUG EFFECTS; FIBROSIS; GENE EXPRESSION; GENETICS; HEART; HEART VENTRICLE; HEART VENTRICLE REMODELING; MALE; METABOLISM; PATHOLOGY; RAT; WISTAR RAT;

ANIMALS; ANTIOXIDANTS; CARDIOTONIC AGENTS; CARDIOTOXICITY; CASPASE 3; DOXORUBICIN; FIBROSIS; GENE EXPRESSION; GLUTATHIONE; HEART; HEART VENTRICLES; MALE; RATS; RATS, WISTAR; RNA, MESSENGER; STILBENES; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA1; VENTRICULAR REMODELING;

EID: 84933045942     PISSN: 11387548     EISSN: 18778755     Source Type: Journal    
DOI: 10.1007/s13105-014-0339-y     Document Type: Article

References (51)

1. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y (2004) Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 24:2783–2840
2. Al-Abd AM, Mahmoud AM, El-Sherbiny GA, El-Moselhy MA, Nofal SM, El-Latif HA, El-Eraky WI, El-Shemy HA (2011) Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro. Cell Prolif 44(6):591–601
3. Arunachalam S, Kim SY, Lee SH, Lee YH, Kim MS, Yun BS, Yi HK, Hwang PH (2012) Davallialactone protects against adriamycin-induced cardiotoxicity in vitro and in vivo. J Nat Med 66:149–157
4. Beutler E, Duron O, Kelly BM (1963) Improved method for the determination of blood glutathione. J Lab Clin Med 61:882–888
5. Cao Z, Li Y (2004) Potent induction of cellular antioxidants and phase 2 enzymes by resveratrol in cardiomyocytes: protection against oxidative and electrophilic injury. Eur J Pharmacol 489(1–2):39–48
6. Chan V, Fenning A, Iyer A, Hoey A, Brown L (2011) Resveratrol improves cardiovascular function in DOCA-salt hypertensive rats. Curr Pharm Biotechnol 12:429–436
7. Crowell JA, Korytko PJ, Morrissey RL, Booth TD, Levine BS (2004) Resveratrol-associated renal toxicity. Toxicol Sci 82(2):614–619
8. Danz ED, Skramsted J, Henry N, Bennett JA, Keller RS (2009) Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. Free Radic Biol Med 46:1589–1597
9. Dernek S, Ikizler M, Erkasap N, Ergun B, Koken T, Yilmaz K, Sevin B, Kaygisiz Z, Kural T (2004) Cardioprotection with resveratrol pretreatment: improved beneficial effects over standard treatment in rat hearts after global ischemia. Scand Cardiovasc J 38(4):245–254
10. Díaz-Chávez J, Fonseca-Sánchez MA, Arechaga-Ocampo E, Flores-Pérez A, Palacios-Rodríguez Y, Domínguez-Gómez G, Marchat LA, Fuentes-Mera L, Mendoza-Hernández G, Gariglio P, López-Camarillo C (2013) Proteomic profiling reveals that resveratrol inhibits hsp27 expression and sensitizes breast cancer cells to doxorubicin therapy. PLoS One 8(5):e64378
11. Dudka J, Gieroba R, Korga A, Burdan F, Matysiak W, Jodlowska-Jedrych B, Mandziuk S, Korobowicz E, Murias M (2012) Different effects of resveratrol on dose-related doxorubicin-induced heart and liver toxicity. Evid Based Complement Alternat Med 2012:606183
12. Elberry AA, Abdel-Naim AB, Abdel-Sattar EA, Nagy AA, Mosli HA, Mohamadin AM, Ashour OM (2010) Cranberry (Vaccinium macrocarpon) protects against doxorubicin-induced cardiotoxicity in rats. Food Chem Toxicol 48:1178–1184
13. El Boghdady NA (2013) Antioxidant and antiapoptotic effects of proanthocyanidin and ginkgo biloba extract against doxorubicin-induced cardiac injury in rats. Cell Biochem Funct 31:344–351
14. Fujita M, Shannan JM, Morikawa O, Gauldie J, Hara N, Masan RJ (2003) Overexpression of tumor necrosis factor-alpha diminishes pulmonary fibrosis induced by bleomycin or transforming growth factor-beta. Am J Respir Cell Mol Biol 29:1–7
15. Gu J, Song ZP, Gui DM, Hu W, Chen YG, Zhang DD (2012) Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in lymphoma nude mice by heme oxygenase-1 induction. Cardiovasc Toxicol 12(4):341–349
16. Guo R, Lin J, Xu W, Shen N, Mo L, Zhang C, Feng J (2013) Hydrogen sulfide attenuates doxorubicin-induced cardiotoxicity by inhibition of the p38 MAPK pathway in H9c2 cells. Int J Mol Med 31:644–650
17. Gupta SC, Kannappan R, Reuter S, Kim JH, Aggarwal BB (2011) Chemosensitization of tumors by resveratrol. Ann N Y Acad Sci 1215:150–160
18. Han X, Ren D, Fan P, Shen T, Lou H (2008) Protective effects of naringenin-7-O-glucoside on doxorubicin-induced apoptosis in H9C2 cells. Eur J Pharmacol 581:47–53
19. Holly TA, Drincic A, Byun Y, Nakamura S, Harris K, Klocke FJ, Cryns VL (1999) Caspase inhibition reduces myocyte cell death induced by myocardial ischemia and reperfusion in vivo. J Mol Cell Cardiol 31(9):1709–1715
20. Juan ME, Vinardell MP, Planas JM (2002) The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J Nutr 132(2):257–260
21. Kasdallah-Grissa A, Mornagui B, Aouani E, Hammami M, El May M, Gharbi N, Kamoun A, El-Fazaâ S (2007) Resveratrol, a red wine polyphenol, attenuates ethanol-induced oxidative stress in rat liver. Life Sci 80(11):1033–1039
22. Kavas GO, Ayral PA, Elhan AH (2013) The effects of resveratrol on oxidant/antioxidant systems and their cofactors in rats. Adv Clin Exp Med 22(2):151–155
23. Kliment CR, Suliman HB, Tobolewski JM, Reynolds CM, Day BJ, Zhu X, McTiernan CF, McGaffin KR, Piantadosi CA, Oury TD (2009) Extracellular superoxide dismutase regulates cardiac function and fibrosis. J Mol Cell Cardiol 47:730–742
24. Koti BC, Vishwanathswamy AH, Wagawade J, Thippeswamy AH (2009) Cardioprotective effect of lipistat against doxorubicin induced myocardial toxicity in albino rats. Indian J Exp Biol 47:41–46
25. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, Imaizumi T (2002) Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 106(1):130–135
26. Li Y, Liu Y, Fu Y, Wei T, Le Guyader L, Gao G, Liu RS, Chang YZ, Chen C (2012) The triggering of apoptosis in macrophages by pristine graphene through the MAPK and TGF-beta signaling pathways. Biomaterials 33:402–411
27. Lowry OH, Rosebrough N, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265–275
28. Migrino RQ, Aggarwal D, Konorev E, Brahmbhatt T, Bright M, Kalyanaraman B (2008) Early detection of doxorubicin cardiomyopathy using two-dimensional strain echocardiography. Ultrasound Med Biol 34:208–214
29. Mohamed HE, Asker ME, Ali SI, El-Fattah TM (2004) Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4. J Pharm Pharmacol 56:757–768
30. Nishikimi M, Roa NA, Yogi K (1972) The occurrence of superoxide anion in the reaction of reduced phenazine methosulfate and molecular oxygen. Biochem Bioph Res Common 46:849–854
31. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL (2012) Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 52:1213–1225
32. Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–358
33. Oktem G, Uysal A, Oral O, Sezer ED, Olukman M, Erol A, Akgur SA, Bilir A (2012) Resveratrol attenuates doxorubicin-induced cellular damage by modulating nitric oxide and apoptosis. Exp Toxicol Pathol 64(5):471–479
34. Osman AM, Al-Harthi SE, Alarabi OM, Elshal MF, Ramadan WS, Alaama MN, Al-Kreathy HM, Damanhouri ZA, Osman OH (2013) Chemosensetizing and cardioprotective effects of resveratrol in doxorubicin- treated animals. Cancer Cell Int 13(1):52
35. Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, Brown K (2011) Clinical trials of resveratrol. Ann N Y Acad Sci 1215:161–169
36. Rezk YA, Balulad SS, Keller RS, Bennett JA (2006) Use of resveratrol to improve the effectiveness of cisplatin and doxorubicin: study in human gynecologic cancer cell lines and in rodent heart. Am J Obstet Gynecol 194:23–26
37. Scoditti E, Calabriso N, Massaro M, Pellegrino M, Storelli C, Martines G, De Caterina R, Carluccio MA (2012) Mediterranean diet polyphenols reduce inflammatory angiogenesis through MMP-9 and COX-2 inhibition in human vascular endothelial cells: a potentially protective mechanism in atherosclerotic vascular disease and cancer. Arch Biochem Biophys 527:81–89
38. Shen M, Wu RX, Zhao L, Li J, Guo HT, Fan R, Cui Y, Wang YM, Yue SQ, Pei JM (2012) Resveratrol attenuates ischemia/reperfusion injury in neonatal cardiomyocytes and its underlying mechanism. PLoS One 7(12):e51223
39. Shuai YI, Guo IB, Peng S-G, Li-Shi Z, Guo J, Han G, Shen Dong Y (2007) Metallothionein protects against doxorubicin-induced cardiomyopathy through inhibition of superoxide generation and related nitrosative impairment. Toxicol Lett 170:66–74
40. Smoliga JM, Baur JA, Hausenblas HA (2011) Resveratrol and health—a comprehensive review of human clinical trials. Mol Nutr Food Res 55:1129–1141
41. Sõti C, Nagy E, Giricz Z, Vígh L, Csermely P, Ferdinandy P (2005) Heat shock proteins as emerging therapeutic targets. Br J Pharmacol 146(6):769–780
42. Tatlidede E, Sehirli O, Velioğlu-Oğünc A, Cetinel S, Yeğen BC, Yarat A, Süleymanoğlu S, Sener G (2009) Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage. Free Radic Res 43(3):195–205
43. Ueno M, Kakinuma Y, Yuhki K, Murakoshi N, Iemitsu M, Miyauchi T, Yamaguchi I (2006) Doxorubicin induces apoptosis by activation of caspase-3 in cultured cardiomyocytes in vitro and rat cardiac ventricles in vivo. J Pharmacol Sci 101:151–158
44. Ungvari Z, Bagi Z, Feher A, Recchia FA, Sonntag WE, Pearson K, de Cabo R, Csiszar A (2010) Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am J Physiol Heart Circ Physiol 299:H18–H24
45. Usta E, Mustafi M, Walker T, Ziemer G (2011) Resveratrol suppresses apoptosis in intact human cardiac tissue—in vitro model simulating extracorporeal circulation. J Cardiovasc Surg (Torino) 52:399–409
46. Vitaglione P, Ottanelli B, Milani S, Morisco F, Caporaso N, Fogliano V (2009) Dietary trans-resveratrol bioavailability and effect on CCl4-induced liver lipid peroxidation. J Gastroenterol Hepatol 24(4):618–622
47. Wang B, Hao J, Jones SC, Yee MS, Roth JC, Dixon IM (2002) Decreased Smad 7 expression contributes to cardiac fibrosis in the infarcted rat heart. Am J Physiol Heart Circ Physiol 282:H1685–H1696
48. Wang GY, Wang YM, Zhang LN, Li Q, Yue H, Song CM, Feng JK, Wang N (2007) Effect of resveratrol on heart function of rats with adriamycin-induced heart failure. Zhongguo Zhong Yao Za Zhi 32(15):1563–1565
49. Xu X, Chen K, Kobayashi S, Timm D, Liang Q (2012) Resveratrol attenuates doxorubicin-induced cardiomyocyte death via inhibition of p70 S6 kinase 1-mediated autophagy. J Pharmacol Exp Ther 341(1):183–195
50. Yu W, Fu YC, Wang W (2012) Cellular and molecular effects of resveratrol in health and disease. J Cell Biochem 113:752–759
51. Zhang C, Lin G, Wan W, Li X, Zeng B, Yang B, Huang C (2012) Resveratrol, a polyphenol phytoalexin, protects cardiomyocytes against anoxia/reoxygenation injury via the TLR4/NF-κB signaling pathway. Int J Mol Med 29:557–563